Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving anti-viral therapy
Sara Battistella 1 , Erica N Lynch 1 , Martina Gambato 1 , Alberto Zanetto 1 , Monica Pellone 1 , Sara Shalaby 1 , Salvatore Sciarrone 1 , Alberto Ferrarese 1 , Giacomo Germani 1 , Marco Senzolo 1 , Patrizia Burra 1 , Francesco P Russo 2
Affiliations
Affiliations
1
Gastroenterology and Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy.
2
Gastroenterology and Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy - [email protected].
Hepatitis B virus is a major health problem worldwide, with approximatively 240 million people living with a chronic HBV infection. HBV chronic infection remains the major cause of hepatocellular carcinoma worldwide, with more than half of HCC patients being chronic HBV carriers, even if underlying mechanisms of tumourigenesis are not totally understood. HBV-related HCC can be prevented by reducing the exposure to HBV by vaccination or by treatment of CHB infection. Current treatment of CHB are Peg-IFN alpha and oral NUCs. Treating HBV infection, either with IFN or NUCs, substantially reduces the risk of HCC development, even if anti-viral therapy fails to completely eliminate HCC risk. Among treated patients, cirrhosis, HBeAg negative at baseline, and failure to remain in virological remission were associated with an increased risk of HCC. The reduction of the risk of developing HCC during anti-viral therapy is largely dependent upon the maintenance of virological remission, since viral load is found to be the most important factor leading to cirrhosis and its complications, including liver cancer development. The question whether Peg-IFN-alpha is superior to NUCs and whether there is a superior agent among NUCs is still controversial. Several studies demonstrated that anti-viral therapy with NUCs could reduce the risk of HCC recurrence after curative treatment of HBV-related HCC. 作者: StephenW 时间: 2020-11-23 19:22
接受抗病毒治疗的HBV相关肝病患者的肝细胞癌风险
萨拉·巴蒂斯特拉（Sara Battistella）1，埃里卡·林奇（Erica N Lynch）1，马丁娜·甘巴托（Martina Gambato）1，阿尔贝托·扎内托（Alberto Zanetto）1，莫妮卡·佩隆（Monica Pellone）1，萨拉·莎拉比（Sara Shalaby）1，萨尔瓦托·希亚罗内（Salvatore Sciarrone）1，阿尔贝托·费拉雷斯（Alberto Ferrarese）1，贾科莫·日耳曼尼（Giacomo Germani）1，马可·森佐洛（Marco Senzolo）1，Patrizia Burra 1，弗朗切斯科·普鲁索（Francesco P Russo）2
隶属关系
隶属关系